Clinical Trials Logo

Esophagogastric Adenocarcinoma clinical trials

View clinical trials related to Esophagogastric Adenocarcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06123468 Recruiting - Clinical trials for Esophagogastric Adenocarcinoma

Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Start date: April 17, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma

NCT ID: NCT05504720 Recruiting - Clinical trials for Esophagogastric Adenocarcinoma

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Start date: February 13, 2023
Phase: Phase 2
Study type: Interventional

The study is an open-label, single arm, multicenter phase II trial investigating the clinical activity of a perioperative therapy consisting of a combination of pembrolizumab, trastuzumab and FLOT, followed by pembrolizumab plus trastuzumab alone for a maximum systemic treatment duration of one year in patients with Her-2 positive localized esophagogastric adenocarcinoma.

NCT ID: NCT04219137 Recruiting - Clinical trials for Esophagogastric Adenocarcinoma

Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study

MOCHA
Start date: November 14, 2019
Phase:
Study type: Observational

Researchers are looking to further our knowledge on disease biology and treatment selection for gastroesophageal adenocarcinoma. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients for the future.